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Abstract
Cytomegalovirus (CMV) retinitis is a complication of patients infected with human immunodeﬁciency virus (HIV) in advance
stage when CD4 count is less than 50 cells/cumm. Before the introduction of highly active antiretroviral therapy (HAART),
approximately 30% of patients with AIDS developed CMV retinitis, which declined in 75% of cases after the start of HAART.
We report a case of CMV retinitis in an HIV-positive patient who developed it as a WHO clinical stage 4 condition
representing clinical failure along with dramatic decrease in CD4 count due to immunological failure on failing ﬁrst-line
HAART.
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Introduction
Cytomegalovirus (CMV) retinitis is a rare disease that
mainly affects patients with acquired immune deﬁciency
syndrome (AIDS). It can also be found in immunosuppressed
patients such as organ transplant recipients on immunosup-
pressive drugs, patients on chemotherapy, and patients with
systemic lupus erythematosus.[1,2] CMV retinitis is the most
common manifestation of end-organ CMV disease among
patients with AIDS.[3,4] CMV disease mostly represents
reactivation in persons with latent CMV infection.[5] The risk
of developing CMV retinitis depends on the degree of
immunosupression; approximately 30% of patients with AIDS
developed CMV retinitis before the start of highly active
antiretroviral therapy (HAART).[6] Studies have shown that
CMV retinitis occurs mostly at CD4 count less than 50 cells/
cumm.[5,6] With the use of potent antiretroviral therapy, the
incidence of CMV retinitis has declined in 75% of cases.[7]
Nowadays, CMV retinitis occurs in HIV-positive patients who
despite having low CD4 count (o50 cells/cumm) are not on
HAART or have repeatedly failed HAART.
The initial symptoms of CMV retinitis comprise ﬂoaters,
ﬂashes, ﬁeld defects, and falling vision that is generally
unilateral to start with. Typically, CMV retinal lesions appear as
areas of white necrosis with edema along the distribution of
retinal vessels with associated hemorrhages. CMV retinitis is
managed initially for 14–21 days with induction therapy
followed by maintenance therapy, which is discontinued if
the patient has inactive retinitis and maintains a CD4 count
more than 100–150 cells/cumm for at least 3–6 months.
According to the recommendation from the Centers for
Disease Control and Prevention, the National Institute of
Health, and the HIV Medicine Association/Infectious Diseases
Society of America, the initial therapy for CMV retinitis should
be based on location and severity of lesions, underlying
immunosupression, adherence factor, and other factors such
as use of concomitant medication.[5] Certain HIV specialists
recommend the use of oral valganciclovir with intraocular
ganciclovir implant for initial therapy (especially for patients
with immediate site-threatening retinitis), but some experts
recommend the use of oral valganciclovir alone for initial
therapy mainly because of its ease of administration and lack
of requirement for ophthalmologic surgery or placement of an
indwelling catheter.[5] Even with the use of intraocular
ganciclovir pellet, concurrent systemic therapy is strongly
recommended to prevent disease in the contralateral eye and
to prevent dissemination to other organs.[8]
Case Report
A 27-year-old man was detected to be HIV positive in May
2011 with initial CD4 count of 42 cells/cumm and was started
on HAART (zidovudine + 3 lamivudine + nevirapine) along
with cotrimoxazole prophylaxis after unremarkable opportu-
nistic infection screen. Two months after the start of therapy,
Access this article online
Website: http://www.ijmsph.com
Quick Response Code:
DOI: 10.5455/ijmsph.2015.150820142
International Journal of Medical Science and Public Health | 2015 | Vol 4 | Issue 1142
Case Report
he developed pulmonary tuberculosis and was on antituber-
culosis treatment for 6 months along with continuation of
HAART. His CD4 count increased to 266 cells/cumm in
November 2011 and to 344 cells/cumm in August 2012.
Thereafter, in March 2013 his CD4 count fell to 202 cells/
cumm due to less than 95% adherence to HAART. He was
counseled and was continued with the same regime. In
October 2013, he presented with painless, progressive
diminution of vision of the right eye for 3 months. On ocular
examination, his vision in the right eye was 1/60 and that in the
left eye was 6/6. Slit lamp biomicroscopic examination showed
normal anterior segment of both eyes. Fundus examination of
the right eye showed white necrosis with edema located along
the distribution of retinal vessels associated with hemorrhage
in zones 1 and 2 [Figure 1], whereas fundus examination of
the left eye was within normal limits. Optical coherence
tomography of the right eye showed extensive necrosis of the
fovea, resulting in signiﬁcant destruction of the retinal nerve
ﬁber layer. Based on the nature of lesion, the following
differential diagnosis was thought of as HIV-associated
retinopathy, toxoplasmosis, varicella-zoster retinitis, and
CMV retinitis. Laboratory diagnosis of CMV retinitis was
conﬁrmed with positive results of serologic testing for CMV
(IgM and IgG) along with CD4 count of 68 cells/cumm. CMV
retinitis being a stage 4 condition according to the WHO
staging for HIV, clinical failure in the patient was thought
of along with immunological failure. He was started on second-
line HAART, which comprised tab tenofovir 300 mg once
daily (OD), tab lamivudine 150 mg BD, tab lopinavir/ritonavir
(200/50 mg) 2 tab BD along with cotrimoxazole prophylaxis,
and tab azithromycin 1200 mg weekly. Induction phase of
CMV retinitis was started with tab valganciclovir 900 mg BD
for 21 days along with twice weekly monitoring of complete
blood count, serum electrolytes, and renal function test. Eye
examination at the end of induction therapy showed no
improvement of the visual status in the right eye, but showed
dramatic improvement in the retinal whitening on fundus
examination. Maintenance therapy with tablet valganciclovir
900 mg OD was continued for 4 months till April 2014 when his
CD4 count was found to be 314 cells/cumm, and fundus
examination showed scarring at the site of the previous
retinitis in the right eye but no improvement in the visual status.
His follow-up CD4 count in August 2014 was 412 cells/cumm,
and no recurrence of CMV retinitis lesions or evidence of any
disseminated CMV disease was observed.
Discussion
CMV retinitis is typically found in immunocompromised
patients, mainly in patients with HIV.[8] Visser[7] while studying
HIV-positive patients observed that approximately 30% of
patients with AIDS developed CMV retinitis before the start of
HAART. The rate declined in 75% of cases after the start
of HAART.[7] Our case shows an immunosuppressed patient
who developed his ﬁrst episode of CMV retinitis as a condition
indicating clinical failure along with immunological failure due
to HIV infection on ﬁrst-line HAART with more than 95%
adherence.
Zone 1 (central lesion) is sight threatening but retinitis in
zones 2 and 3 has no major symptom except for a peripheral
ﬁeld defect, as seen in our case where the patient reported
late with vision loss on involvement of zone 1 (central lesion)
because the symptoms prevailed for the last 3 months.
At the time of initial presentation with active CMV retinitis,
approximately 30% of patients presented with visual acuity of
20/50 or worse and 17% had 20/200 or worse.[9] Thus, it is
important for patients with low CD4 count to be educated
about the symptoms of CMV retinitis and should be instructed
to seek urgent eye evaluation by ophthalmologist so as to
prevent CMV retinitis–induced blindness. In the modern era of
potent antiretroviral therapy, the incidence of CMV retinitis has
declined dramatically[6] with most cases occurring in patients
with HIV not on HAART despite low CD4 count or who have
repeatedly failed antiretroviral therapy.[10] As seen in our case,
the individual had witnessed decrease in CD4 count to 202
cells/cumm in March 2013 from 344 cells/cumm in August
2012 because of poor adherence to recommended HAART
with repeated dramatic decrease in CD4 count again to 68
cells/cumm in October 2013 when presented with CMV retinitis
in right eye due to immunological failure probably because of
drug resistance despite good adherence to HAART this time.
In our case, initial ophthalmological evaluation showed that
there was extensive damage to the macula and the individual
had already lost his substantial vision, so we used oral
valganciclovir alone for the induction phase therapy followed
by maintenance therapy till his CD4 count sustained more
than 200 cells/cumm for 4 months. Oral valganciclovir therapy,
in our case, has shown resolution of CMV retinitis lesions
in the affected eye and has prevented CMV disease
Figure 1: Fundus examination of the right eye showed white necrosis
with edema located along the distribution of retinal vessels associated
with hemorrhage in zones 1 and 2
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dissemination to the other eye and systemic organs when
followed up for 9 months posttreatment.
Conclusion
CMV retinitis can occur as AIDS-deﬁning illness in patients
due to repeated failed antiretroviral therapy. Patients with HIV
infection need to be educated about symptoms of CMV retinitis
such as ﬂoaters, ﬂashes, ﬁeld defects, and fall in vision so that
they can be seen by the ophthalmologist at early stage of
disease condition and prevent CMV-induced blindness. Oral
valganciclovir alone during induction and maintenance therapy
is effective in prevention of systemic dissemination of CMV
disease and resolution of CMV lesions in affected eye when
the vision has been substantially lost on presentation.
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